524 related articles for article (PubMed ID: 24532543)
1. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
Angoulvant F; Levy C; Grimprel E; Varon E; Lorrot M; Biscardi S; Minodier P; Dommergues MA; Hees L; Gillet Y; Craiu I; Zenkhri F; Dubos F; Guen CG; Launay E; Martinot A; Cohen R
Clin Infect Dis; 2014 Apr; 58(7):918-24. PubMed ID: 24532543
[TBL] [Abstract][Full Text] [Related]
2. Impact of PCV13 on community-acquired pneumonia by C-reactive protein and procalcitonin levels in children.
Levy C; Biscardi S; Dommergues MA; Dubos F; Hees L; Levieux K; Aurel M; Minodier P; Zenkhri F; Cohen R;
Vaccine; 2017 Sep; 35(37):5058-5064. PubMed ID: 28778617
[TBL] [Abstract][Full Text] [Related]
3. Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children.
Ouldali N; Levy C; Minodier P; Morin L; Biscardi S; Aurel M; Dubos F; Dommergues MA; Mezgueldi E; Levieux K; Madhi F; Hees L; Craiu I; Gras Le Guen C; Launay E; Zenkhri F; Lorrot M; Gillet Y; Béchet S; Hau I; Martinot A; Varon E; Angoulvant F; Cohen R
JAMA Pediatr; 2019 Apr; 173(4):362-370. PubMed ID: 30715140
[TBL] [Abstract][Full Text] [Related]
4. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
[TBL] [Abstract][Full Text] [Related]
5. Pneumococcal conjugate vaccines decrease community-acquired alveolar pneumonia with and without pleural effusion in children <60 months in Southern Israel, 2002-2016.
Triadou D; Givon-Lavi N; Greenberg D; Ben-Shimol S
Infect Dis (Lond); 2020 Mar; 52(3):186-195. PubMed ID: 31774020
[No Abstract] [Full Text] [Related]
6. Evaluation of the Impact of Pneumococcal Conjugate Vaccine on Pediatric Community-Acquired Pneumonia Using an Emergency Database System.
Noel G; Viudes G; Laporte R; Minodier P
J Pediatric Infect Dis Soc; 2017 Jun; 6(2):129-133. PubMed ID: 27125271
[TBL] [Abstract][Full Text] [Related]
7. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay.
Pletz MW; Ewig S; Rohde G; Schuette H; Rupp J; Welte T; Suttorp N; Forstner C;
Vaccine; 2016 Apr; 34(20):2342-8. PubMed ID: 27016653
[TBL] [Abstract][Full Text] [Related]
8. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
[TBL] [Abstract][Full Text] [Related]
9. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.
Rodrigo C; Bewick T; Sheppard C; Greenwood S; Mckeever TM; Trotter CL; Slack M; George R; Lim WS
Eur Respir J; 2015 Jun; 45(6):1632-41. PubMed ID: 25792633
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.
Takeuchi N; Naito S; Ohkusu M; Abe K; Shizuno K; Takahashi Y; Omata Y; Nakazawa T; Takeshita K; Hishiki H; Hoshino T; Sato Y; Ishiwada N
Epidemiol Infect; 2020 Apr; 148():e91. PubMed ID: 32299523
[TBL] [Abstract][Full Text] [Related]
11. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
[TBL] [Abstract][Full Text] [Related]
12. Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines.
Principi N; Esposito S
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28029140
[TBL] [Abstract][Full Text] [Related]
13. Rethinking number-needed-to-vaccinate for pneumococcal conjugate vaccines in older adults: Current and future implications.
McLaughlin JM; Swerdlow DL; Isturiz RE; Jodar L
Vaccine; 2017 Sep; 35(40):5360-5365. PubMed ID: 28863866
[TBL] [Abstract][Full Text] [Related]
14. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
[TBL] [Abstract][Full Text] [Related]
15. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
Isturiz R; Webber C
Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
[TBL] [Abstract][Full Text] [Related]
16. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
[TBL] [Abstract][Full Text] [Related]
17. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.
Esposito S; Principi N;
Future Microbiol; 2015; 10(10):1599-607. PubMed ID: 26439470
[TBL] [Abstract][Full Text] [Related]
18. Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.
Syrogiannopoulos GA; Michoula AN; Tsimitselis G; Vassiou K; Chryssanthopoulou DC; Grivea IN
Infect Dis (Lond); 2016 Oct; 48(10):749-53. PubMed ID: 27320108
[TBL] [Abstract][Full Text] [Related]
19. A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada.
Vadlamudi NK; Patrick DM; Rose C; Sadatsafavi M; Hoang L; Marra F
Vaccine; 2022 Feb; 40(7):1047-1053. PubMed ID: 35012778
[TBL] [Abstract][Full Text] [Related]
20. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
